Drug Profile

SG 2501

Alternative Names: Recombinant anti-cluster of differentiation 38(CD38)/47(CD47) bispecific antibody; SG-2501

Latest Information Update: 03 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hangzhou Sumgen Biotech
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; Macrophage stimulants; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

25 Mar 2025 Hangzhou Sumgen Biotech terminates a phase I trial in Haematological malignancies (Second-line therapy or greater, Monotherapy) in USA (IV) due to adjustment in clinical development plan (NCT05293912)
03 Aug 2022 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater, Monotherapy) in USA (IV) (NCT05293912)
31 Mar 2022 Preclinical trials in Haematological malignancies in USA (Parenteral) (NCT05293912)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com